share_log

Earnings Call Summary | Sonendo(SONX.US) Q1 2024 Earnings Conference

Earnings Call Summary | Sonendo(SONX.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Sonendo (SONX.US) 2024 年第一季度業績會議
moomoo AI ·  05/11 15:03  · 電話會議

The following is a summary of the Sonendo, Inc. (SONX) Q1 2024 Earnings Call Transcript:

以下是索南多公司(SONX)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Sonendo Inc reported Q1 revenue of $7 million, surpassing their prediction, but experienced a dip compared to the Q1 of 2023's $8.7 million.

  • Gross GAAP margin increased to 28%, a rise compared to last year's Q1's 23%.

  • The firm has seen a year-over-year improvement of 700 basis points, raising its non-operational GAAP gross margin to 30%.

  • Against a backdrop of a 41% reduction, the company managed to reduce its non-GAAP operating loss from $12.8 million to $7.5 million.

  • The 2024 full-year revenue guidance was increased to $29 million to $31 million based on early successes and confidence in the strategy.

  • Sonendo Inc公佈的第一季度收入爲700萬美元,超過了他們的預期,但與2023年第一季度的870萬美元相比有所下降。

  • GAAP毛利率增至28%,與去年第一季度的23%相比有所上升。

  • 該公司的非運營公認會計准則毛利率同比增長了700個點子,將其非運營性GAAP毛利率提高到30%。

  • 在下降41%的背景下,該公司設法將其非公認會計准則營業虧損從1,280萬美元減少至750萬美元。

  • 基於早期的成功和對該戰略的信心,2024年全年收入預期增加至2900萬美元至3,100萬美元。

Business Progress:

業務進展:

  • The company treated 1.4 million patients, marking its progress.

  • With only 20% of its endodontists performing the GentleWave procedure in the U.S. and Canada, there is considerable room for expansion.

  • A strategic business reset is underway to focus on operations efficiency, strategic selling practices, and positive return on investment commercial programs.

  • Having successfully received more console orders than shipped, the firm has a healthy backlog of sales orders.

  • The company anticipates a gradual increase in gross margin over the year with strategic sourcing, material cost reductions, and value engineering.

  • Commercial execution, cash conservation, and margin expansion are key future focuses, with the aim to return to double-digit revenue growth in 2025.

  • While awaiting cavity approval, the firm is reducing its emphasis on general dentistry, focusing more on endodontics, and emphasizing cash conservation, commercial execution, and margin expansion.

  • 該公司治療了140萬名患者,標誌着其進展。

  • 在美國和加拿大,只有20%的牙髓專家進行GentleWave手術,因此還有很大的擴張空間。

  • 正在進行戰略業務重組,將重點放在運營效率、戰略銷售實踐和正投資回報商業計劃上。

  • 該公司成功收到的主機訂單多於發貨量,因此積壓的銷售訂單相當可觀。

  • 該公司預計,通過戰略採購、材料成本降低和價值工程,全年毛利率將逐步提高。

  • 商業執行、現金保護和利潤擴張是未來的主要重點,目標是在2025年恢復兩位數的收入增長。

  • 在等待牙科批准的同時,該公司減少了對普通牙科的重視,將重點更多地放在牙髓治療上,並強調現金保存、商業執行和利潤擴大。

More details: Sonendo IR

更多詳情: Sonendo IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論